ArticleCureus2026
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Onset in Pregnancy: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune demyelinating disorder of the central nervous system in which optic neuritis is a frequent manifestation. Its presentation during pregnancy may pose a diagnostic challenge because bilateral optic disc edema and headache can mimic idiopathic intracranial hypertension or hypertensive disorders of pregnancy. We report a 39-year-old primigravid woman at 31 weeks of gestation with gestational diabetes and class III obesity who presented with progressive bifrontal headache followed by transient bilateral blurred vision, dyschromatopsia, and sudden severe visual loss in the right eye. Ophthalmologic examination showed bilateral papilledema, a relative afferent pupillary defect in the right eye, and reduced visual acuity. Ultrasound demonstrated an enlarged optic nerve sheath diameter, while brain and spine magnetic resonance imaging showed no major abnormalities. Visual evoked potentials revealed bilateral conduction delay, more severe in the right eye. Lumbar puncture showed a normal opening pressure (19.5 cmH2O) and normal cerebrospinal fluid cytochemistry, but cerebrospinal fluid-restricted oligoclonal bands were detected. Given the clinical suspicion of inflammatory optic neuropathy, serum testing for demyelinating disorders was performed and was positive for anti-myelin oligodendrocyte glycoprotein (MOG) antibodies, whereas aquaporin-4 and systemic autoimmune antibodies were negative. The patient was treated with intravenous methylprednisolone followed by therapeutic plasma exchange because of limited initial response, with progressive visual recovery and no maternal or fetal complications. This case highlights that MOG-associated optic neuritis should be considered in pregnant patients with acute visual loss and bilateral optic disc edema. Intracranial hypertension was ruled out, and paraclinical studies concluded bilateral inflammatory optic neuritis. Early recognition, serologic confirmation, and timely immunotherapy are essential to improve visual outcomes. Careful postpartum follow-up is warranted because relapse risk may increase after delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.